|
|
Drugs for Renal Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 217)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Sunitinib | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 510 | 341031-54-7, 557795-19-4 | 5329102 | (2S)-2-hydroxybutanedioic acid 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) 326914-13-0 341031-54-7 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE 557795-19-4 AC1NS62J AC1O5CMQ AKOS005145765 Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) CHEBI:38940 CHEBI:550864 CHEMBL1567 CHEMBL535 CID5329102 CID6456015 D06402 D08552 DB01268 DB07417 EN002687 FT-0083555 FT-0083556 I01-1229 K00588a KS-5022 LS-186078 LS-187023 LS-187648 MolPort-003-986-763 N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide NCGC00164631-01 | NSC736511 NSC750690 PDGF TK antagonist PHA-290940AD PNU-290940AD S1042_Selleck ST51053712 SU 011248 SU 11248 SU-010398 SU-011248 L-malate salt SU-11248 SU-11248 L-malate salt SU-11248J SU-12662 SU010398 SU011248 SU011248 L-malate salt SU11248 Su-011248 Sunitanib Sunitinib Sunitinib (INN) Sunitinib (free base) Sunitinib malate Sunitinib malate (JAN/USAN) Sunitinib malate [USAN] Sunitinibum Sutent Sutent (TN) Sutent, SU-11248 TL8002546 UNII-LVX8N1UT73 UNII-V99T50803M sunitinib sunitinibum | |
| | 2 | | Bevacizumab | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 2020 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 3 | | Aldesleukin | approved | Phase 4, Phase 2, Phase 1, Early Phase 1 | 405 | 85898-30-2, 110942-02-4 | | 125-L-serine-2-133-interleukin 2 (human reduced) | Interleukin-2 aldesleukin Interleukin-2(2-133),125-ser Recombinant interleukin-2 human |
| | 4 | | Axitinib | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 109 | 319460-85-0 | 6450551 | 319460-85-0 790713-39-2 AC-1539 AC1O51X3 AG 013736 AG-013736 AG-013736, Axitinib AG-13736 AG013736 Axitinib C503983 CID6450551 | EC-000.2322 I14-1971 INLYTA Inlyta MolPort-006-392-413 N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide S1005_Selleck ST51054130 UNII-C9LVQ0YUXG ZINC03816287 axitinib axitinibum | |
| | 5 | | nivolumab | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 424 | 946414-94-4 | | | MDX-1106 ONO-4538 nivolumab |
| | 6 | | Angiogenesis Modulating Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 4185 | | | | 7 | | Protein Kinase Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 3689 | | | | 8 | | Angiogenesis Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1 | 4257 | | | | 9 | | Interleukin-2 | | Phase 4, Phase 2, Phase 1, Early Phase 1 | 571 | | | | 10 | | Anti-Infective Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 22062 | | | | 11 | | Anti-HIV Agents | | Phase 4, Phase 2, Phase 1, Early Phase 1 | 3162 | | | | 12 | | Anti-Retroviral Agents | | Phase 4, Phase 2, Phase 1, Early Phase 1 | 3296 | | | | 13 | | Antiviral Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 9967 | | | | 14 | | Antibodies | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 6394 | | | | 15 | | Antibodies, Monoclonal | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 4039 | | | | 16 | | Immunoglobulins | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 6394 | | | | 17 | | Peripheral Nervous System Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 23689 | | | | 18 | | Analgesics, Non-Narcotic | | Phase 4, Phase 2, Phase 1, Early Phase 1 | 6501 | | | | 19 | | Analgesics | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 11733 | | | | 20 | | Vincristine | approved, investigational | Phase 3, Phase 2 | 922 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 21 | | Doxorubicin | approved, investigational | Phase 3, Phase 2 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 22 | | Etoposide | approved | Phase 3, Phase 2, Phase 1 | 1269 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 23 | | Dactinomycin | approved | Phase 3, Phase 2 | 48 | 50-76-0 | 2019, 457193 | (- )-actinomycin d (-)-actinomycin d -pentone 01815_FLUKA 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 50-76-0 A1410_SIGMA A4262_SIGMA A9415_SIGMA AC1L1CQX AC1L9W52 ACT ACT D ACTINOMYCIN D ACTINOMYCIN D AMP ACTINOMYCIN-D ACTO-D ACon0_000471 ACon1_001004 AD AD (VAN) AI3-26374 ActD Actactinomycin A IV Actactinomycin a Iv Actinomycin 11 Cosmegen Actinomycin 11 cosmegen Actinomycin 7 Actinomycin A IV Actinomycin Aiv Actinomycin C (sub1) Actinomycin C(sub1) Actinomycin C1 Actinomycin D Actinomycin D (JP15) Actinomycin D deriv. of 3H-phenoxaocardazine Actinomycin D, sodium deoxyribonucleic acid complex Actinomycin I Actinomycin I (sub1) Actinomycin I(sub 1) Actinomycin I(sub1) Actinomycin I1 Actinomycin IV Actinomycin Iv Actinomycin X 1 Actinomycin X1 Actinomycin iv Actinomycin-(threo-val-pro-sar-meval) Actinomycin-?IV Actinomycin-[threo-val-pro-sar-meval] Actinomycindioic D Acid, Dilactone Actinomycindioic D acid, dilactone Acto-D Antibiotic From Streptomyces Parvullus Antibiotic from Streptomyces parvullus BCBcMAP01_000155 BRD-A42383464-001-02-2 Bio1_000342 Bio1_000831 Bio1_001320 C06770 C1 C62H86N12O16 CBiol_002056 CCRIS 9 CHEBI:123721 CHEBI:27666 CHEMBL1554 CHEMBL427947 CID2019 | CID457193 COSMEGEN (TN) CPD000469227 Chounghwamycin B Cosmegen D Actinomycin D00214 DACTINOMYCIN DB00970 DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA Dactinomicina Dactinomicina [INN-Spanish] Dactinomycin Dactinomycin (USP) Dactinomycin D Dactinomycin [USAN:BAN] Dactinomycine Dactinomycine [INN-French] Dactinomycinum Dactinomycinum [INN-Latin] Dilactone Actinomycin D Acid Dilactone Actinomycindioic D Acid Dilactone actin omycindioic D acid Dilactone actinomycin D acid Dilactone actinomycindioic D acid EINECS 200-063-6 FT-0080366 GNF-PF-1977 HBF 386 HBF 386 Meractinomycin HBF 386 meractinomycin HMS2052O17 HSDB 3220 LMPK14000005 LS-142 Lyovac Cosmegen Lyovac cosmegen MEGxm0_000350 MLS001424196 Meractinomycin MolPort-001-739-741 MolPort-003-925-177 NCGC00025059-02 NCGC00090796-01 NCGC00161622-01 NCGC00161622-02 NCGC00169767-01 NCI-C04682 NCI60_030539 NP-005932 NSC 3053 NSC-3053 NSC191297 NSC3053 Neuro_000003 Oncostatin K Oxamide PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA SAM001246846 SMP1_000005 SMR000469227 UNII-1CC1JFE158 UPCMLD-DP055 UPCMLD-DP055:001 UPCMLD-DP055:002 WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1 X 97 actd actinomycin D actinomycin cl actinomycin x i actinomyein-theo-val-pro-sar-meval dactinomyein d o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine |
| | 24 | | Everolimus | approved | Phase 3, Phase 2, Phase 1 | 1940 | 159351-69-6 | 6442177 | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy 07741_FLUKA 159351-69-6 40-O-(2-hydroxyethyl)-rapamycin 42-O-(2-Hydroxyethyl)rapamycin Afinitor CERTICAN(R) CHEMBL1201755 Certican D02714 DB01590 | Everolimus Everolimus (JAN/USAN/INN) Everolimus [USAN] LS-143292 MolPort-003-847-342 MolPort-003-925-588 NCGC00167512-01 NVP-RAD-001 RAD 001 RAD-001 RAD-001C RAD001 RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus S1120_Selleck SDZ-RAD UNII-9HW64Q8G6G Zortress everolimus |
| | 25 | | Carboplatin | approved | Phase 3, Phase 2, Phase 1 | 2050 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 26 | | Sirolimus | approved, investigational | Phase 3, Phase 2, Phase 1 | 1940 | 53123-88-9 | 5284616, 6436030, 46835353 | (-)-Rapamycin (-)-rapamycin 1fkb 1pbk 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 53123-88-9 A422989, NSC226080 AC-722 AC1L1JH9 AC1L7MJ9 AC1L9ZMV AY 22989 AY-22989 AY22989 Ambotz53123-88-9 Antibiotic AY 22989 BIDD:PXR0165 Bio1_000293 Bio1_000782 Bio1_001271 Bio2_000375 Bio2_000855 BiomolKI2_000084 C07909 C51H79NO13 CBiol_002007 CCRIS 9024 CHEBI:100923 CHEBI:9168 CHEMBL413 CID10213190 CID10795871 CID11949238 CID11959112 CID313006 CID478951 CID5040 CID5284616 CID5358081 CID5374464 CID5460439 CID5497196 CID5924240 CID6436030 CID6610270 CID6610346 CID6711160 CID6713081 CID9833581 CID9854379 CID9854380 CID9962926 CID9962928 D00753 DB00877 DE-109 DivK1c_006936 | FT-0082351 HMS2089A21 HSDB 7284 KBio1_001880 KBio2_000410 KBio2_002978 KBio2_005546 KBio3_000779 KBio3_000780 KBioGR_000410 KBioSS_000410 LCP-Siro LMPK06000003 LS-143290 MLS000028373 MS-R001 MolMap_000043 MolPort-003-959-433 NCGC00021305-05 NCI60_001851 NCIMech_000355 NSC 226080 NSC226080 Perceiva QTL1_000069 R0395_SIAL R0395_SIGMA RAP RAPA RPM Rapammune Rapamune Rapamune (TN) Rapamycin Rapamycin (TN) Rapamycin C-7, analog 4 Rapamycin Immunosuppressant Drug Rapamycin from Streptomyces hygroscopicus S1039_Selleck SIIA 9268A SILA 9268A SILA9268A SMP1_000255 SMR000058564 Sirolimus Sirolimus (RAPAMUNE) Sirolimus (USAN/INN) Sirolimus [USAN:BAN:INN] Sirolimus, Rapamune,Rapamycin SpecPlus_000840 UNII-W36ZG6FT64 UNM-0000358684 WY-090217 Wy 090217 heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy nchembio.100-comp4 nchembio.2007.42-comp2 nchembio.79-comp1 nchembio762-comp1 nchembio883-comp3 rapamycin sirolimus |
| | 27 | | Miconazole | approved, investigational, vet_approved | Phase 3, Phase 2, Phase 1 | 3706 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Micantin (nitrate) Miconasil Nitrate | Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole | |
| | 28 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2, Phase 1 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 29 | | Trimethoprim | approved, vet_approved | Phase 3 | 177 | 738-70-5 | 5578 | 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine 46984_FLUKA 46984_RIEDEL 5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine 738-70-5 92131_FLUKA 92131_SIGMA AB00052118 AB1004879 AC-13572 AC1L1KNQ AC1Q48DF AI3-52594 AKOS001650069 ARONIS24118 AZT + TMP/SMX (mixture) combination Abacin Abaprim Alcorim-F Alprim Anitrim Antrima Antrimox Apo-Sulfatrim BB_SC-2116 BIDD:GT0190 BPBio1_000215 BRD-K07208025-001-06-5 BRN 0625127 BSPBio_000195 BSPBio_002245 BW 56-72 BW 5672 BW-56-72 Bacdan Bacidal Bacide Bacin Bacta Bacterial Bacterial [Antibiotic] Bacticel Bactin Bactoprim Bactramin Bactrim Bactrim DS Bactrim Pediatric Baktar Bencole Bethaprim Biosulten Briscotrim C01965 CAS-738-70-5 CCRIS 2410 CHEBI:45924 CHEMBL22 CID5578 CPD0-1581 CPD000035999 Chemotrim Chemotrin Cidal Co-Trimoxizole Co-trimoxazole Colizole Colizole DS Comox Conprim Cotrim Cotrim D.S. Cotrimel D00145 D014295 DB00440 Deprim DivK1c_000589 Drylin Duocide EINECS 212-006-2 EU-0101271 Esbesul Espectrin Euctrim Eusaprim Exbesul Fectrim Fermagex Fortrim Futin Gantaprim Gantrim HMS1568J17 HMS1921I03 HMS2090D14 HMS2092A10 HMS501N11 HSDB 6781 I06-0086 IDI1_000589 Idotrim Ikaprim Imexim Instalac Ipral KBio1_000589 KBio2_000647 KBio2_003215 KBio2_005783 KBio3_001465 KBioGR_000863 KBioSS_000647 KSC-4-158 KUC103659N Kepinol Kombinax LS-1627 Lagatrim Lagatrim Forte Laratrim Lastrim Lidaprim Linaris Lopac-T-7883 Lopac0_001271 MLS000079023 MLS001201740 MLS002303068 Methoprim Metoprim Microtrim MolPort-001-826-685 Monoprim Monotrim Monotrimin NCGC00016055-01 NCGC00016055-02 NCGC00016055-06 NCGC00016055-12 NCGC00024707-01 NCGC00024707-03 NCGC00024707-04 NCGC00024707-05 NCGC00024707-06 NCGC00024707-07 NCGC00024707-08 NIH 204 | NIH 204 (VAN) NINDS_000589 NSC 106568 NSC-106568 NSC106568 Nopil Novotrimel Omstat Oprea1_495058 Oraprim Pancidim Polytrim Prestwick0_000208 Prestwick1_000208 Prestwick2_000208 Prestwick3_000208 Prestwick_485 Priloprim Primosept Primsol Proloprim Proloprim (TN) Protrin Purbal Resprim Resprim Forte Roubac Roubal SAM002264649 SMP2_000262 SMR000035999 SPBio_000874 SPBio_002116 SPECTRUM1500595 STK177322 Salvatrim Septra Septra DS Septra Grape Septrin Septrin DS Septrin Forte Septrin S Setprin Sigaprim Sinotrim Smz-Tmp Spectrum2_000937 Spectrum3_000643 Spectrum4_000372 Spectrum5_001559 Spectrum_000167 Stopan Streptoplus Sugaprim Sulfamar Sulfamethoprim Sulfamethoprim-DS Sulfamethoxazole & Trimethoprim Sulfatrim Sulfatrim Pediatric Sulfatrim-DS Sulfatrim-SS Sulfotrim Sulfoxaprim Sulmeprim Sulmeprim Pediatric Sulprim Sulthrim Sultrex Sumetrolim Supracombin Suprim Syraprim T 7883 T2286 T7883_SIGMA TCMDC-125538 TL8005108 TMP/SMX (MIXTURE)) Teleprim Thiocuran Tiempe Tmp-Ratiopharm Tocris-0650 Toprim Trigonyl Trimanyl Trimesulf Trimeth/Sulfa Trimethioprim Trimethopim(TMP) Trimethoprim Trimethoprim & VRC3375 Trimethoprim (JAN/USP/INN) Trimethoprim [USAN:BAN:INN:JAN] Trimethoprime Trimethoprime [INN-French] Trimethoprimum Trimethoprimum [INN-Latin] Trimethopriom Trimetoprim Trimetoprim [DCIT] Trimetoprim [Polish] Trimetoprima Trimetoprima [INN-Spanish] Trimexazole Trimexol Trimez-IFSA Trimezol Trimogal Trimono Trimopan Trimpex Trimpex (TN) Trimpex 200 Triméthoprime Triprim Trisul Trisulcom Trisulfam Trisural U-Prin UNII-AN164J8Y0X UPCMLD-DP132 UPCMLD-DP132:001 Unitrim Uretrim Uro-D S Uro-Septra Urobactrim Uroplus Uroplus DS Uroplus SS Utetrin Velaten WLN: T6N CNJ BZ DZ E1R CO1 DO1 EO1 WR 5949 Wellcoprim Wellcoprin Xeroprim ZINC06627681 Zamboprim component of Bactrim component of Septra nchembio.108-comp1 nchembio.215-comp11 nchembio.221-comp23 trimethoprim | |
| | 30 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 31 | | Methylphenidate | approved, investigational | Phase 3 | 375 | 113-45-1 | 4158 | .alpha.-Phenyl-2-piperidineacetic acid methyl ester 113-45-1 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester 2-Piperidineacetic acid, alpha-phenyl-, methyl ester 298-59-9 (hydrochloride) 4311/B Ciba AC1L1HJM C 4311 C07196 CHEBI:6887 CHEMBL796 CID4158 Calocain Centedein Centedrin Centedrine Centredin Concerta D-Methylphenidate HCl D04999 DB00422 DB06701 DEA No. 1724 Daytrana Daytrana (TN) EINECS 204-028-6 Focalin Focalin XR HSDB 3126 L001307 LS-565 METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R) MPH Meridil Metadate Metadate CD Metadate ER MethyPatch Methyl (2-phenyl-2-(2-piperidyl)acetate) Methyl alpha-phenyl-alpha-(2-piperidyl)acetate Methyl alpha-phenyl-alpha-2-piperidinylacetate Methyl phenidate | Methyl phenidyl acetate Methyl phenidylacetate Methylfenidan Methylin Methylin ER Methylofenidan Methylphen Methylphenidan Methylphenidate Methylphenidate (USAN/INN) Methylphenidate HCl Methylphenidate [INN:BAN] Methylphenidate hydrochloride Methylphenidatum Methylphenidatum [INN-Latin] Methylphenidylacetate hydrochloride Methypatch Metilfenidat hydrochloride Metilfenidato Metilfenidato [INN-Spanish] Metilfenidato [Italian] MolPort-001-779-620 NCI-C56280 PMS-Methylphenidate Phenidylate Plimasine Riphenidate Ritalin Ritalin LA Ritalin SR Ritalin hydrochloride Ritalin-SR Ritaline Ritcher Works Ritcher works Tsentedrin UNII-207ZZ9QZ49 alpha-Phenyl-2-piperidineacetic acid methyl ester alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester d-methylphenidate HCl methyl 2-phenyl-2-piperidin-2-ylacetate methyl phenyl(piperidin-2-yl)acetate methylphenidate nchembio.2007.55-comp28 |
| | 32 | | Paclitaxel | approved, vet_approved | Phase 3, Phase 1 | 2864 | 33069-62-4 | 36314 | (2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 157069-30-2 33069-62-4 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv. 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. 7-Epi-Paclitaxel 7-Epi-Taxol 7-Epipaclitaxel 7-Epitaxol 7-epi-Paclitaxel 7-epi-Taxol AB00513812 ABI 007 ABI-007 ABI007 AC-675 AC1L1IOG AC1L1VJI AC1L9AVF ACon1_002231 ANX-513 Abraxane Abraxane (TN) Abraxane I.V. Suspension Abraxis BioScience brand of albumin-bound paclitaxel Ambotz33069-62-4 Anzatax Asotax BIDD:PXR0046 BMS 181339-01 BMS-181339 BMS-181339-01 BPBio1_000320 BRD-A23723433-001-01-2 BRD-A28746609-001-04-0 BRD-K62008436-001-03-1 BSPBio_000290 BSPBio_001152 BSPBio_002614 Bio-0076 Bio1_000362 Bio1_000851 Bio1_001340 Bio2_000416 Bio2_000896 Bristaxol C07394 C466458 C47H51NO14 CCRIS 8143 CHEBI:103439 CHEBI:45863 CHEMBL100910 CHEMBL418410 CHEMBL48 CID36314 CID441276 CID4666 CID6713921 CID6915727 CPD-8718 Capxol D00491 DB01229 DHP-107 DHP-208 DRG-0190 DTS-301 DivK1c_000441 EU-0101201 Ebetaxel EmPAC Epitaxol Genaxol Genetaxyl Genexol Genexol-PM HMS1362J13 HMS1568O12 HMS1792J13 HMS1922K08 HMS1990J13 HMS2090D07 HMS2093K15 HMS501G03 HSDB 6839 I06-0014 IDI1_000441 IDI1_002171 Intaxel KBio1_000441 KBio2_000492 KBio2_002016 KBio2_002509 KBio2_003060 KBio2_004584 KBio2_005077 KBio2_005628 KBio2_007152 KBio2_007645 KBio3_000903 KBio3_000904 KBio3_001834 KBio3_002987 KBioGR_000492 KBioGR_001893 | KBioGR_002509 KBioSS_000492 KBioSS_002016 KBioSS_002517 LMPR0104390001 LS-31070 LipoPac Lopac0_001201 MBT 0206 MEGxp0_001940 MLS000863266 MLS001077297 MLS002154218 MLS002172439 MLS002695976 MPI-5018 Micellar Paclitaxel Mitotax MolPort-001-742-627 MolPort-003-665-783 MolPort-003-932-365 NCGC00024995-02 NCGC00024995-03 NCGC00024995-04 NCGC00024995-05 NCGC00024995-06 NCGC00024995-07 NCGC00164367-01 NCGC00164367-02 NCGC00164367-03 NCI60_000601 NINDS_000441 NK 105 NP-010981 NSC 125973 NSC-125973 NSC125973 NSC358882 Nanotaxel Neuro_000060 Nova-12005 OAS-PAC-100 OncoGel Onxal Onxol Onxol, Taxol, Nov-Onxol, Paclitaxel P1632 Paclical Pacligel Paclitaxel Paclitaxel (JAN/USP) Paclitaxel (JAN/USP/INN) Paclitaxel (Taxol) Paclitaxel [USAN:INN:BAN] Paxceed Paxene Paxoral Plaxicel Praxel Prestwick0_000155 Prestwick1_000155 Prestwick2_000155 Prestwick3_000155 Probes2_000350 QW 8184 S-8184 Paclitaxel Injectable Emulsion S1150_Selleck SDCCGMLS-0066823.P001 SDP-013 SMP1_000228 SMR000394086 SMR000857385 SPBio_000943 SPBio_002229 SPECTRUM1503908 ST50306996 Spectrum2_000872 Spectrum3_001057 Spectrum4_001197 Spectrum5_001491 Spectrum_001536 T 7402 T1912_SIGMA T7191_SIGMA T7402_SIGMA TA1 TAXOL (TN) TAXOL, 10-EPI, TXL TaxAlbin Taxol Taxol A Taxol Konzentrat Taxol.RTM. (Registered Trademark) UNII-P88XT4IS4D UPCMLD-DP108:001 UPCMLD-DP108:002 Vascular Wrap Xorane Yewtaxan abi-007 albumin-bound paclitaxel cMAP_000068 nab-paclitaxel nchembio.188-comp1 nchembio.2007.34-comp9 nchembio.215-comp9 nchembio853-comp6 paclitaxel weekly paclitaxel |
| | 33 | | Morphine | approved, investigational | Phase 3 | 1007 | 57-27-2 | 5288826 | (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (-)-Heroin hydrochloride (-)-Morphine (-)Morphine sulfate (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol (5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol (−)-morphine 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol 4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol 47106-99-0 57-27-2 6211-15-0 (sulfate (2:1) (salt) pentahydrate) 64-31-3 64-31-3 (sulfate (2:1) (salt) anhydrous) 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol 8053-16-5 85201-37-2 Apokyn Astramorph PF Avinza BIDD:GT0147 C01516 CCRIS 5762 CHEBI:17303 CHEMBL70 CID5288826 Cube juice D-(-)-Morphine DB00295 DEA No. 9300 DepoDur Depodur Diacetylmorphine hydrochloride Diamorphine hydrochloride Dolcontin Dreamer Dulcontin Duramorph PF Duromorph EINECS 200-320-2 Epimorph HSDB 2134 Hard stuff Heroin hydrochloride Heroine hydrochloride Hocus | Infumorph Kadian LS-91748 M-Eslon M.O.S MOI MORPHINE SULFATE MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE MS Contin MS/L MS/S MSIR Meconium MolPort-003-849-273 Morfina Morfina [Italian] Morphia Morphin Morphin [German] Morphina Morphina [Italian] Morphine Extra-Forte Morphine Forte Morphine H.P Morphine Sulfate Morphine [BAN] Morphinism Morphinum Morphitec Morphium Morpho Moscontin Ms Contin Ms Emma NSC11441 Nepenthe O,O'-Diacetylmorphine hydrochloride OMS Concentrate Oramorph SR Ospalivina RMS RMS Uniserts Rescudose Roxanol Roxanol 100 Roxanol UD SDZ 202-250 SDZ202-250 Statex Statex Drops Statex SR UNII-76I7G6D29C Unkie l-Morphine morfina morphine nchembio.317-comp1 nchembio.64-comp1 |
| | 34 | | Mechlorethamine | approved | Phase 3, Phase 2, Phase 1 | 397 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 35 | | Ifosfamide | approved | Phase 3, Phase 2, Phase 1 | 400 | 3778-73-2 | 3690 | (+-)-Ifosfamid (+-)-Ifosphamide (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (D,L)-Ifosfamide (R,S)-Ifosphamide (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI) 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 3,} 2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 36341-88-5 3778-73-2 84711-20-6 A 4942 AB00513932 AC-2113 AC1L1GHW ASTA Z 4942 Ambap3778-73-2 Asta Z 4942 BPBio1_000865 BRN 0611835 BSPBio_000785 C07047 CAS-3778-73-2 CCRIS 352 CHEBI:5864 CHEMBL1024 CID3690 Cyfos D00343 D007069 DB01181 EINECS 223-237-3 HMS1570H07 HMS2090M12 HMS2093N07 HSDB 7023 Holoxan Holoxan 1000 I-Phosphamide I06-0494 IFEX (TN) Ifex Ifosfamid Ifosfamida Ifosfamida [INN-Spanish] Ifosfamide (JAN/USP/INN) | Ifosfamide Sterile Ifosfamide [USAN:INN:BAN:JAN] Ifosfamidum Ifosfamidum [INN-Latin] Ifosphamide Ifsofamide Iphosphamid Iphosphamid(e) Iphosphamide Iso Endoxan Iso-Endoxan Isoendoxan Isofosfamide Isophosphamide Isosfamide LS-102 LS-99799 MJF 9325 MJF-9325 MLS002154021 Mitoxana Mitoxana, Ifex, Ifosfamide MolPort-003-666-704 N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German] N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine NCGC00016639-01 NCGC00179435-01 NCI-C01638 NCI60_000233 NPFAPI-04 NSC 109,724 NSC 109724 NSC-109,724 NSC-109724 NSC109,724 NSC109724 Naxamide Prestwick0_000833 Prestwick1_000833 Prestwick2_000833 Prestwick3_000833 S1302_Selleck SMR001233348 SPBio_002706 STL058690 UNII-UM20QQM95Y WLN: T6NPOTJ AM2G BO B2G Z 4942 Z-4942 Z4942 ifosfamide isosfamide {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1, | |
| | 36 | | Fentanyl | approved, illicit, investigational, vet_approved | Phase 3 | 821 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 1-phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl CII Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 Fentanyl-12 Fentanyl-25 | Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze UNII-UF599785JZ fentanyl | |
| | 37 | | Sulfamethoxazole | approved | Phase 3 | 161 | 723-46-6 | 5329 | 129378-89-8 3-(Para-Aminophenylsulphonamido)-5-methylisoxazole 3-(p-Aminobenzenesulfonamido)-5-methylisoxazole 3-(p-Aminophenylsulfonamido)-5-methylisoxazole 3-(para-Aminophenylsulphonamido)-5-methylisoxazole 3-Sulfanilamido-5-methylisoxazole 3-Sulphanilamido-5-methylisoxazole 4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide 4-Amino-N-(5-methyl-3-isoxazolyl)-Benzenesulfonamide 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide 4-Amino-N-[5-methyl-3- isoxazolyl]benzenesulfonamide 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide 46850_RIEDEL 5-Methyl-3-sulfanilamidoisoxazole 5-Methyl-3-sulfanylamidoisoxazole 5-Methyl-3-sulfonylamidoisoxazole 5-Methyl-3-sulphanil-amidoisoxazole 723-46-6 A047 AB00052099 AC-11118 AC1L1K42 AC1Q2J5R AKOS000200952 ALBB-002089 ARONIS018156 Apo-Sulfamethoxazole Azo Gantanol Azo-Gantanol Azo-gantanol BAS 00836086 BB_SC-1251 BIDD:GT0731 BPBio1_000081 BRD-K28494619-001-05-0 BRN 0226453 BSPBio_000073 BSPBio_002028 Bactrim Bactrimel C07315 C10H11N3O3S CAS-723-46-6 CCRIS 567 CHEBI:9332 CHEMBL443 CID5329 CPD000058223 D00447 D013420 DB01015 DivK1c_000649 EINECS 211-963-3 Gamazole Gantanol Gantanol (TN) Gantanol (tn) Gantanol-DS HMS1568D15 HMS1921A21 HMS2092K03 HMS502A11 HMS561O18 HSDB 3186 I01-0154 IDI1_000649 InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13) KBio1_000649 KBio2_001474 KBio2_004042 KBio2_006610 KBio3_001528 KBioGR_000749 KBioSS_001474 LS-1620 MLS000069732 MLS001055354 MLS001074165 MS 53 Maybridge1_007190 Metoxal MolPort-000-145-787 N'-(5-Methyl-3-isoxazole)sulfanilamide | N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide N'-(5-Methyl-3-isoxazolyl)sulfanilamide N'-(5-Methylisoxazol-3-yl)sulphanilamide N(Sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide N1-(5-Methyl-3-isoxazolyl)sulfanilamide N1-(5-Methyl-3-isoxazolyl)sulphanilamide N1-(5-Methylisoxazol-3-yl)sulfanilamide N1-(5-methyl-3-isoxazolyl)-Sulfanilamide NCGC00016533-01 NCGC00016533-02 NCGC00021995-03 NCGC00021995-04 NCGC00021995-05 NINDS_000649 NSC 147832 NSC147832 N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide Oprea1_114486 Oprea1_285680 Prestwick0_000177 Prestwick1_000177 Prestwick2_000177 Prestwick3_000177 Prestwick_453 Radonil Ro 4-2130 Ro 6-2580/11 Ro-4-2130 S0361 S1915_Selleck S7507_FLUKA S7507_SIGMA SAM002554930 SIM SMR000058223 SMX SPBio_000896 SPBio_001994 SPECTRUM1500550 STK007988 SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE) Septran Simsinomin Sinomin Solfametossazolo Solfametossazolo [DCIT] Spectrum2_000788 Spectrum3_000584 Spectrum4_000345 Spectrum5_000982 Spectrum_000994 Sulfamethalazole Sulfamethoxazol Sulfamethoxazole Sulfamethoxazole (JP15/USP/INN) Sulfamethoxazole [USAN:INN:JAN] Sulfamethoxazole sodium Sulfamethoxazole(USAN) Sulfamethoxazolum Sulfamethoxazolum [INN-Latin] Sulfamethoxizole Sulfamethylisoxazole Sulfametoxazol Sulfametoxazol [INN-Spanish] Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI) Sulfisomezole Sulpha-Methoxizole Sulpha-methoxizole Sulphamethalazole Sulphamethoxazol Sulphamethoxazole Sulphamethoxazole BP 98 Sulphamethylisoxazole Sulphisomezole TL8005058 TMP/SMX (MIXTURE)) Trib UNII-JE42381TNV Urobak WLN: T5NOJ C1 EMSWR DZ ZINC00089763 nchembio.221-comp24 sulfamethoxazole |
| | 38 | | Sorafenib | approved, investigational | Phase 3, Phase 2, Phase 1 | 700 | 284461-73-0 | 216239, 406563 | 284461-73-0 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AB1004622 AC-1674 AC1L50CF BAX BAY 43-9006 BAY 43-9006 (free base) BAY 43-9006 tosylate salt BAY 439006 BAY 54-9085 (tosylate salt) BAY-43-0006 BAY-43-9006 BAY-54-9085 BAY43-9006 BRD-K23984367-001-01-8 Bio-0100 CHEBI:47228 CHEBI:50924 CHEMBL1336 CID216239 | D08524 DB00398 DB07438 EN002709 I06-0856 K00597a Kinome_766 LS-186067 LS-187021 LS-187788 MolPort-003-850-270 N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea NCGC00167488-01 NSC-724772 NSC747971 Nexavar STK627350 Sorafenib Sorafenib (INN) Sorafenib [INN] Sorafenib tosylate Sorafenibum UNII-9ZOQ3TZI87 ZINC01493878 nchembio.117-comp17 sorafenib sorafenibum | |
| | 39 | | Pembrolizumab | approved | Phase 3, Phase 2, Phase 1 | 507 | 1374853-91-4 | | | | 40 | | Minocycline | approved, investigational | Phase 3 | 231 | 10118-90-8 | 5281021 | (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE (4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 10118-90-8 13614-98-7 (mono-hydrochloride) 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide 4708-96-7 7-Dimethylamino-6-demethyl-6-deoxytetracycline AC1NQXWM Alti-Minocycline Apo-Minocycline Arestin BRN 3077644 Bio-0062 Borymycin C07225 C23H27N3O7 CHEBI:50694 CHEBI:529981 CHEMBL1434 CHEMBL259172 CID5281021 CL 59806 CRL-1605 & Minocycline D05045 Dynacin Gen-Minocycline HMS2090D03 HSDB 3130 Klinomycin | LMPK07000002 LS-93850 Lactoferrin B & Minocycline Lactoferrin H & Minocycline MINO MIY Minociclina Minociclina [INN-Spanish] Minociclinum Minocin Minocin (Hydrochloride) Minocline Minocyclin Minocycline (USAN/INN) Minocycline HCl Minocycline Monohydrochloride Minocycline [USAN:BAN:INN] Minocyclinum Minocyclinum [INN-Latin] Minocyn Minomycin NCGC00178854-01 NSC 141993 NSC141993 Novo-Minocycline Solodyn UNII-FYY3R43WGO Vectrin Vectrin (Hydrochloride) minociclinum minocycline nchembio.559-comp1 |
| | 41 | | Niacin | approved, investigational, nutraceutical | Phase 3, Phase 1, Phase 2 | 923 | 59-67-6 | 938 | 3-Carboxylpyridine 3-Carboxypyridine 3-Pyridinecarboxylate 3-Pyridinecarboxylic acid 3-Pyridylcarboxylate 3-Pyridylcarboxylic acid 3-carboxypyridine Acide Nicotinique Acido nicotinico Acidum Nicotinicum Akotin Anti-pellagra vitamin Apelagrin Daskil Efacin Enduracin Linic M-Pyridinecarboxylic Acid Niac Niacin Niacine Niacor Nicacid Nicamin Nicangin | Nico-Span Nicobid Nicocap Nicodelmine Nicolar Niconacid Nicosan 3 Nicotinate Nicotinic Acid Nicotinic acid Nicotinipca Nicyl Nikotinsaeure Nyclin P.P. factor PP Factor Pellagra preventive factor Pellagrin Pelonin Pyridine-beta-carboxylic acid Slo-niacin Vitamin B3 Wampocap beta-Pyridinecarboxylic acid pyridine-β-carboxylic acid β-pyridinecarboxylic acid | |
| | 42 | | Nicotinamide | approved, Nutraceutical | Phase 3, Phase 1, Phase 2 | 919 | 98-92-0 | 936 | .beta.-Pyridinecarboxamide 11032-50-1 123574-63-0 1yc5 3 Pyridinecarboxamide 3-Carbamoylpyridine 3-Pyridinecarboxamide 3-Pyridinecarboxylic acid amide 37321-14-5 47865U_SUPELCO 55600-01-6 63748-44-7 72340_FLUKA 72340_SIGMA 72347_FLUKA 78731-47-2 98-92-0 A186B02E-6C70-4E54-9739-79398D439AAA AC-907/25014114 AC1L1ACZ AC1Q4ZFV AI3-02906 Acid amide Amid kyseliny nikotinove Amid kyseliny nikotinove [Czech] Amide PP Aminicotin Amixicotyn Amnicotin Astra Brand of Niacinamide Austrovit PP B 3, Vitamin B3, Vitamin BB_NC-2290 Benicot C00153 C6H6N2O CCRIS 1901 CHEBI:17154 CHEMBL1140 CID936 CPD000058212 D00036 D009536 DB02701 DEA No. 1405 Delonin Amide Delonin amide Dipegyl Dipigyl EINECS 202-713-4 EINECS 234-265-0 Endobion Enduramide Factor pp HMS2052M21 HMS2090B05 HMS2093H03 HSDB 1237 Hansamid I02-1741 I02-2250 InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9 Inovitan PP Jenapharm Brand of Niacinamide Jenapharm, Nicotinsaureamid LS-2051 MLS000069714 Mediatric Merck Brand of Niacinamide MolMap_000061 MolPort-001-783-876 N0078 N0636_SIGMA N2142_SIGMA N3376_SIGMA N5535_SIAL NAM NCGC00093354-03 NCGC00093354-04 NSC 13128 NSC13128 NSC27452 Nandervit-N Niacevit Niacinamide Niacinamide (USP) Niacinamide Astra Brand Niacinamide Jenapharm Brand Niacinamide Merck Brand | Niacinamide Pharmagenix Brand Niacinamide [USAN] Niacinamide, Nicotinic acid amide, Nicotinamide Niacotinamide Niamide Niavit PP Nicamide Nicamina Nicamindon Nicasir Nicobion Nicofort Nicogen Nicomidol Nicosan 2 Nicosylamide Nicota Nicotamide Nicotilamide Nicotililamido Nicotinamid Nicotinamida Nicotinamida [INN-Spanish] Nicotinamide Nicotinamide (JP15/INN) Nicotinamide (Niacinamide) Nicotinamide, niacin, vitamin B3 Nicotinamide-carbonyl-14C Nicotinamidum Nicotinamidum [INN-Latin] Nicotine acid amide Nicotine amide Nicotinic acid amide Nicotinic amide Nicotinsaeureamid Nicotinsaureamid Nicotinsaureamid Jenapharm Nicotinsaureamid [German] Nicotol Nicotylamide Nicotylamidum Nicovel Nicovit Nicovitina Nicovitol Nicozymin Nictoamide Nikasan Nikazan Niko-tamin Nikotinamid Nikotinsaeureamid Nikotinsaeureamid [German] Niocinamide Niozymin PP-Faktor Papulex Pelmin Pelmine Pelonin amide Pharmagenix Brand of Niacinamide Propamine A Pyridine-3-carboxylic acid amide S1899_Selleck SAM001246860 SGCUT00176 SMR000058212 Savacotyl UNII-25X51I8RD4 Vi-Nicotyl Vi-noctyl Vitamin B Vitamin B (VAN) Vitamin B 3 Vitamin B3 amide Vitamin H1 Vitamin PP WLN: T6NJ CVZ Witamina PP ZINC00005878 b-Pyridinecarboxamide beta-Pyridinecarboxamide bmse000281 m-(Aminocarbonyl)pyridine nchembio.154-comp4 nchembio.73-comp6 niacin - Vitamin B3 niacinamide nicotinamide pyridine-3-carboxamide to_000073 vitamin PP |
| | 43 | | Folic Acid | approved, nutraceutical, vet_approved | Phase 3, Phase 1, Phase 2 | 4392 | 59-30-3 | 6037 | (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid 01769_FLUKA 2d0k 33609-88-0 36653-55-1 (mono-potassium salt) 59-30-3 6484-89-5 (mono-hydrochloride salt) AC-11682 AC1L1LNX AI3-26387 AKOS000503224 ARONIS014410 Acfol (Spain) Acide folique Acide folique [INN-French] Acido folico Acido folico [INN-Spanish] Acidum folicum Acidum folicum [INN-Latin] Acifolic Antianemia factor Apo-Folic BIDD:ER0563 BIDD:GT0641 BIF0608 BPBio1_000654 BSPBio_000594 BSPBio_002338 C00504 C20H20N6O6 CAS-59-30-3 CCRIS 666 CHEBI:27470 CHEMBL1622 CID6037 CPD000471860 Cytofol D00070 DB00158 DivK1c_000494 Dosfolat B activ EINECS 200-419-0 F0043 F7876_SIAL F7876_SIGMA F8758_SIGMA F8798_SIAL F8890_SIGMA FOL Facid Factor U Folacid Folacin Folaemin Folaemin [Netherlands] Folan Folasic (Australia) Folate Folbal Folcidin Folcidin (VAN) Folcysteine Foldine Foldine [France] Folettes Foliamin Folic Folic acid Folic acid (JP15/USP/INN) Folic acid (TN) Folic acid [BAN:INN:JAN] Folic acid [INN:BAN:JAN] Folic acid dihydrate Folicet Folicet (TN) Folico Folico (Italy) Folina Folina (Italy) Folipac Folsaeure | Folsan Folsaure Folsav Folvite Folvron Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L HMS1921D20 HMS2092N17 HMS501I16 HSDB 2002 IDI1_000494 InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s Incafolic KBio1_000494 KBio2_001861 KBio2_004429 KBio2_006997 KBio3_001558 KBioGR_002222 KBioSS_001861 Kyselina listova Kyselina listova [Czech] LS-2157 Liver Lactobacillus casei factor MLS001304016 MLS001335861 Millafol Mission prenatal Mittafol MolPort-004-285-551 N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-Pteroyl-L-glutamic acid N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid NCGC00016265-01 NCGC00142391-01 NINDS_000494 NSC 3073 Nifolin Nifolin [Denmark] Novofolacid Novofolacid [Canada] PGA PGA (VAN) Prestwick3_000627 Prestwick_230 PteGlu Pteroyl-L-glutamate Pteroyl-L-glutamic acid Pteroyl-L-monoglutamate Pteroyl-L-monoglutamic acid Pteroylglutamate Pteroylglutamic acid Pteroylmonoglutamate Pteroylmonoglutamic acid SAM002264616 SDCCGMLS-0066738.P001 SMP2_000137 SMR000471860 SPBio_001357 SPECTRUM1502020 Serum Folate Level Spectrum2_001459 Spectrum3_000749 Spectrum4_001751 Spectrum5_000602 Spectrum_001381 UNII-935E97BOY8 Usaf cb-13 Vitamin B11 Vitamin B9 Vitamin Bc Vitamin Be Vitamin M bmse000299 folic acid nchembio.108-comp10 | |
| | 44 | | Doxil | Approved June 1999 | Phase 3, Phase 2 | 1751 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 45 | | Topoisomerase Inhibitors | | Phase 3, Phase 2, Phase 1 | 5069 | | | | 46 | | Nucleic Acid Synthesis Inhibitors | | Phase 3, Phase 2, Phase 1 | 4962 | | | | 47 | | Immunosuppressive Agents | | Phase 3, Phase 2, Phase 1 | 13086 | | | | 48 | | Antifungal Agents | | Phase 3, Phase 2, Phase 1 | 3696 | | | | 49 | | Interferon-alpha | | Phase 3, Phase 2, Phase 1 | 1152 | | | | 50 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1 | 4827 | | |
Interventional clinical trials: (show top 50)
(show all 270)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | Completed | NCT00006864 | Phase 4 | | 2 | Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy | Recruiting | NCT02570789 | Phase 4 | | 3 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors | Recruiting | NCT02700568 | Phase 4 | | 4 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | Recruiting | NCT02982954 | Phase 4 | | 5 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma | Recruiting | NCT01521715 | Phase 4 | | 6 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma | Active, not recruiting | NCT02596035 | Phase 4 | | 7 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma | Terminated | NCT00930345 | Phase 4 | | 8 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | Completed | NCT00606632 | Phase 3 | | 9 | TroVax Renal Immunotherapy Survival Trial | Completed | NCT00397345 | Phase 3 | | 10 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | Completed | NCT00738530 | Phase 3 | | 11 | Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) | Completed | NCT00072046 | Phase 3 | | 12 | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | Completed | NCT00087022 | Phase 3 | | 13 | Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer | Completed | NCT00492258 | Phase 3 | | 14 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | Completed | NCT00326898 | Phase 3 | | 15 | Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors | Completed | NCT00002610 | Phase 3 | | 16 | Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer | Completed | NCT00002611 | Phase 3 | | 17 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 18 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | Completed | NCT00678392 | Phase 3 | | 19 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | Completed | NCT00002641 | Phase 3 | | 20 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | Completed | NCT00002764 | Phase 3 | | 21 | E-MOSAIC Electronic Tool to Monitor Symptoms | Completed | NCT00477919 | Phase 3 | | 22 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | Completed | NCT00483782 | Phase 3 | | 23 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | Recruiting | NCT02883153 | Phase 2, Phase 3 | | 24 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Recruiting | NCT01575548 | Phase 3 | | 25 | Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery | Recruiting | NCT02535351 | Phase 3 | | 26 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | Recruiting | NCT03055013 | Phase 3 | | 27 | Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium | Recruiting | NCT02928692 | Phase 3 | | 28 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Active, not recruiting | NCT01668784 | Phase 3 | | 29 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | Active, not recruiting | NCT01599754 | Phase 3 | | 30 | Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer | Active, not recruiting | NCT01099423 | Phase 3 | | 31 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | Active, not recruiting | NCT01198158 | Phase 3 | | 32 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | Active, not recruiting | NCT01120249 | Phase 3 | | 33 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | Not yet recruiting | NCT01762592 | Phase 3 | | 34 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | Not yet recruiting | NCT03142334 | Phase 3 | | 35 | Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) | Unknown status | NCT01069770 | Phase 2 | | 36 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | Unknown status | NCT01791387 | Phase 2 | | 37 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) | Unknown status | NCT01216371 | Phase 2 | | 38 | Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | Unknown status | NCT00293501 | Phase 1, Phase 2 | | 39 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | Unknown status | NCT00301990 | Phase 2 | | 40 | Immunochemotherapy for Metastatic Renal Cell Carcinoma | Unknown status | NCT00226798 | Phase 2 | | 41 | Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | Unknown status | NCT01824615 | Phase 2 | | 42 | A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | Unknown status | NCT01693822 | Phase 2 | | 43 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer | Unknown status | NCT01784978 | Phase 2 | | 44 | Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | Unknown status | NCT02324803 | Phase 2 | | 45 | Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney | Unknown status | NCT00025103 | Phase 2 | | 46 | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | Completed | NCT02607553 | Phase 2 | | 47 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | Completed | NCT00550277 | Phase 2 | | 48 | Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney | Completed | NCT00853021 | Phase 2 | | 49 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | Completed | NCT00729053 | Phase 2 | | 50 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | Completed | NCT01034631 | Phase 1, Phase 2 |
|
